PROs stratified by LDH response status
In this study, improvement in LDH levels with C5 inhibitor treatment was associated with improvements in FACIT-F and EORTC QLQ-C30 GH scores. Compared with patients with LDH levels ≥ 1.5 × ULN at day 183 (Mean ΔBL PRO scores stratified by LDH levels at day 183 in patients receiving eculizumab or ravulizumab: In patients with LDH levels < 1.5 × ULN at day 183, improvements in mean Hb level were associated with continual improvements in mean FACIT-F score throughout the study period (Fig. Mean ΔBL FACIT-F scores stratified by ΔBL Hb in patients receiving eculizumab or ravulizumab: 